Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADAG
Upturn stock ratingUpturn stock rating

Adagene Inc (ADAG)

Upturn stock ratingUpturn stock rating
$1.45
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: ADAG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.75

1 Year Target Price $5.75

Analysts Price Target For last 52 week
$5.75Target price
Low$1.32
Current$1.45
high$3.58

Analysis of Past Performance

Type Stock
Historic Profit -35.84%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 90.45M USD
Price to earnings Ratio -
1Y Target Price 5.75
Price to earnings Ratio -
1Y Target Price 5.75
Volume (30-day avg) 3
Beta 0.74
52 Weeks Range 1.32 - 3.58
Updated Date 06/30/2025
52 Weeks Range 1.32 - 3.58
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.74

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -17082.39%

Management Effectiveness

Return on Assets (TTM) -21.92%
Return on Equity (TTM) -55.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 23749382
Price to Sales(TTM) 876.42
Enterprise Value 23749382
Price to Sales(TTM) 876.42
Enterprise Value to Revenue 230.12
Enterprise Value to EBITDA 1.12
Shares Outstanding 47109600
Shares Floating 12798488
Shares Outstanding 47109600
Shares Floating 12798488
Percent Insiders 4.7
Percent Institutions 34.89

Analyst Ratings

Rating 2
Target Price 5.75
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Adagene Inc

stock logo

Company Overview

overview logo History and Background

Adagene Inc. is a clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Founded in 2011, Adagene focuses on developing cutting-edge antibody therapies based on its DPL technology platform.

business area logo Core Business Areas

  • Antibody Discovery and Development: Adagene utilizes its Dynamic Precision Library (DPL) technology to discover and develop fully human therapeutic antibodies.
  • Oncology Immunotherapy: The company focuses on developing novel immunotherapies for cancer treatment.
  • Clinical Trials: Adagene conducts clinical trials to evaluate the safety and efficacy of its antibody candidates.

leadership logo Leadership and Structure

The company has a leadership team with experience in biotechnology, drug development, and clinical research. The organizational structure includes research, development, clinical operations, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • ADG106 (CD137 agonist): ADG106 is a fully human, agonistic anti-CD137 IgG4 antibody designed for enhanced safety and efficacy. It's in clinical development for advanced solid tumors. No specific market share data is available at this stage. Competitors include other CD137 agonists in development by various companies.
  • ADG126 (CTLA-4 conditional blocker): ADG126 is a novel masked antibody designed to block CTLA-4 in the tumor microenvironment, potentially reducing systemic toxicity. It's in clinical development. No specific market share data is available at this stage. Competitors include other CTLA-4 inhibitors like ipilimumab (Yervoy) from Bristol-Myers Squibb.
  • ADG116 (Anti-CTLA-4):: An anti-CTLA-4 masked antibody designed to be tumor-microenvironment activated, reducing systemic toxicity. Currently in clinical trials. Competitors are Yervoy and other CTLA-4 inhibitors.

Market Dynamics

industry overview logo Industry Overview

The oncology immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system and the development of novel antibody-based therapies. Competition is intense with many companies developing new cancer treatments.

Positioning

Adagene is positioned as an innovative company leveraging its DPL technology platform to discover and develop differentiated antibody therapies with potentially improved safety and efficacy profiles.

Total Addressable Market (TAM)

The global oncology market is projected to reach hundreds of billions of dollars. Adagene is positioned to capture a portion of this TAM by developing innovative immunotherapies. The exact percentage is unknown and depends on clinical trial success and market penetration.

Upturn SWOT Analysis

Strengths

  • Proprietary DPL technology platform
  • Focus on developing differentiated antibody therapies
  • Experienced management team
  • Pipeline of novel immunotherapies

Weaknesses

  • Clinical-stage company with no products currently on the market
  • Dependence on successful clinical trial outcomes
  • Relatively small market capitalization compared to established pharmaceutical companies
  • Potential for competition from larger pharmaceutical companies

Opportunities

  • Potential to partner with larger pharmaceutical companies
  • Expansion of pipeline through further development of DPL technology
  • Positive clinical trial results leading to regulatory approval
  • Addressing unmet medical needs in oncology

Threats

  • Failure of clinical trials
  • Competition from other immunotherapies
  • Changes in regulatory environment
  • Difficulty in securing financing

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • MRK
  • PFE
  • AZN

Competitive Landscape

Adagene competes with both established pharmaceutical companies and other biotechnology companies in the oncology immunotherapy space. Its competitive advantage lies in its DPL technology and differentiated antibody therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by investment in research and development, advancement of pipeline candidates through clinical trials, and securing partnerships.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its antibody therapies. Analyst estimates vary.

Recent Initiatives: Recent initiatives include progressing clinical trials for ADG106 and ADG126, and exploring new applications of its DPL technology.

Summary

Adagene is a clinical-stage biopharmaceutical company with a promising technology platform for developing novel antibody-based cancer immunotherapies. The company faces the typical risks associated with drug development, but its differentiated approach and strong pipeline provide opportunities for growth. Positive clinical trial results and strategic partnerships will be key to its success. The low market share and high competition highlight the need for Adagene to innovate and execute its strategic plan effectively.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Adagene Inc

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-02-09
Co- Founder, Chairman, CEO and President of R&D Dr. Peter P. Luo Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 138
Full time employees 138

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.